Q3 earnings recap: Winners, losers & surprises
This week, in (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma's reported Q3 earnings. They also tackle what's going on at Pfizer, ADCs, deals and more.
Want to dive deeper on BioSpace? Read more on Pfizer's recent cuts as part of their cost-savings program and more insight on Q3 earnings for Gilead, Novo Nordisk, Moderna, Vertex, BMS, Lilly, GSK.
Lori Ellis is the head of insights at BioSpace, providing research and industry analysis as well as paid custom content for BioSpace clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at email@example.com. Follow her on LinkedIn.
Tyler Patchen is a staff writer at BioSpace. You can reach him at firstname.lastname@example.org. Follow him on LinkedIn.
Also available on Apple podcasts